409A valuation AI Medical Service AOT asset valuation Biotech firms Biotechgate Biotechgate Digital Partnering brain activity measuring breast cancer Cells clinical trial database Cold Ablation Robotguided Laser Osteotome cranio-maxillofacial surgery Cyrill Bätscher early digestive track cancer detection Ferring Pharmaceutical filming Fujieda Ayumi Funding future of life sciences Gergely Ivanyi German Biotech German Life Sciences GTAI Health Made in Germany Heartseed Inc. HelloPartnering in-licensing opportunities JPM San Francisco Kiyoshi Hasegawa life science database Lily MedTech Inc. medical image analysis NeU Corporation patrik frei product valuation RESI Rhine-Main-Neckar biotech SARS CoV 2 Shiho Azuma Tomohiro Tada valuation Valuation Experts XB-01 Yone Production Co Ltd
EVA Therapeutics is primarily focused on rescuing premature newborn babies with respiratory distress syndrome by developing an unprecedented enteral ventilation technology. Learn more about the Osaka-based organization in this installment of our Let’s Interview Series.
Venture Valuation (VV) interviewed OZAKI Hiromu, Co-founder and CEO.
Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?
Metagen Therapeutics is investigating the safety and efficacy of Antibiotic Fecal Microbiota Transplantation (A-FMT) in patients with advanced-stage Parkinson’s disease for microbiome therapeutics development. Learn more about the Yamagata-based organization in this installment of our Let’s Interview Series.
Venture Valuation (VV) interviewed Dr. NAKAHARA Taku, President and CEO.
Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?
Toregem is aiming to commercialize a groundbreaking antibody drug for tooth regeneration. Learn more about the Kyoto-based organization in this installment of our Let’s Interview Series.
Venture Valuation (VV) interviewed Dr. KISO Honoka, D.D.S., Ph.D., Co-founder and CEO.
Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?
Megakaryon is aiming for mass production of the first global iPSC (induced Pluripotent Stem Cell)-derived platelet product for allogeneic use. Learn more about the Kyoto-based organization in this installment of our Let’s Interview Series.
Venture Valuation (VV) interviewed Dr. AKAMATSU Kenichi, CEO, and Mr. AYABE Tsuyoshi, COO & CFO.
Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?
Sound Wave Innovation is developing proprietary LIPUS (Low-Intensity Pulsed Ultrasound) brain therapy, focusing on early-stage Alzheimer’s disease. Learn more about the Tokyo-based organization in this installment of our Let’s Interview Series.
Venture Valuation (VV) interviewed Dr. SHIMOKAWA Hiroaki, Founder & CMO, KATO Hajime, CEO, and MANO Takamitsu, Corporate Director.
Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?
Pixie Dust Technologies invented a new audio method with gamma wave sound to prevent or even improve Alzheimer’s disease. Learn more about the Tokyo-based organization in this installment of our Let’s Interview Series.
Venture Valuation (VV) interviewed TSUJI Mitsutaka, General Manager, and NAGATANI Yoshiki, PhD, Senior Engineer.
Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?
Rebirthel are preparing the first clinical trial conducted in humans for acute myeloid leukemia to evaluate safety and efficacy. Learn more about the Kyoto-based organization in this installment of our Let’s Interview Series.
Venture Valuation (VV) interviewed President and CEO, Mr. Kajikawa Masunori.
Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?
Human Life Cord specialize in allogeneic cell therapy, applying umbilical cord derived mesenchymal stromal cells (MSCs) that are able to differentiate into a variety of cell types. Learn more about the Tokyo-based organization in this installment of our Let’s Interview Series.
Venture Valuation (VV) interviewed President and CEO, Mr. Harata Masamitsu.
Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?
Sonire Therapeutics has commenced a randomized Phase 2 study for the treatment of unresectable pancreatic cancer with their next-generation High-Intensity Focused Ultrasound therapy system. Learn more about the Tokyo-based organization in this installment of our Let’s Interview Series.
Venture Valuation (VV) interviewed President and CEO, Mr. Satoh Toru.
Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?
J-Pharma is a frontrunner in developing inhibitors of L-type amino acid transporter for treating advanced refractory cancers and autoimmune diseases. Learn more about the Yokohama-based organization in this installment of our Let’s Interview Series.
Venture Valuation (VV) interviewed President and CEO, Mr. Max Yoshitake.
Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?
